Link between Genotype and Multi-Organ Iron and Complications in Children with Transfusion-Dependent Thalassemia
Authors:
- Antonella MeloniAntonella Meloni
- Laura PistoiaLaura Pistoia
- Paolo RicchiPaolo Ricchi
- Maria Caterina PuttiMPMaria Caterina Putti
- Maria Rita GamberiniMGMaria Rita Gamberini
- Liana CucciaLCLiana Cuccia
- Giuseppe MessinaGMGiuseppe Messina
- Francesco MasseiFMFrancesco Massei
- Elena FacchiniEFElena Facchini
- Riccardo RighiRRRiccardo Righi
- Stefania RenneSRStefania Renne
- Giuseppe PeritoreGPGiuseppe Peritore
Open Access
- 4 March 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (3) , 400
Abstract
We evaluated the impact of the genotype on hepatic, pancreatic and myocardial iron content, and on hepatic, cardiac and endocrine complications in children with transfusion-dependent β-thalassemia (β-TDT). We considered 68 β-TDT patients (11.98 ± 3.67 years, 51.5% females) consecutively enrolled in the Extension-Myocardial Iron Overload in Thalassemia network. Iron overload was quantified by T2* technique and biventricular function by cine images. Replacement myocardial fibrosis was evaluated by late gadolinium enhancement technique. Three groups of patients were identified: homozygous β+ (N = 19), compound heterozygous β0β+ (N = 24), and homozygous β0 (N = 25). The homozygous β0 group showed significantly lower global heart and pancreas T2* values than the homozygous β+ group. Compared to patients with homozygous β+ genotype, β0β+ as well as β0β0 patients were more likely to have pancreatic iron overload (odds ratio = 6.53 and 10.08, respectively). No difference was detected in biventricular function parameters and frequency of replacement fibrosis. No patient had cirrhosis/fibrosis, diabetes or heart failure, and the frequency of endocrinopathies was comparable among the groups. In pediatric β-TDT patients, there is an association between genotype and cardiac and pancreatic iron overload. The knowledge of patients’ genotype can be valuable in predicting some patients’ phenotypic features and in helping the clinical management of β-TDT patients.Keywords
Funding Information
- Bayer (Italy) (na)
- Chiesi Farmaceutici (na)
This publication has 69 references indexed in Scilit:
- Treating iron overload in patients with non‐transfusion‐dependent thalassemiaAmerican Journal of Hematology, 2013
- Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine MonotherapyJournal of Cardiovascular Magnetic Resonance, 2013
- Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelinesIndian Journal of Endocrinology and Metabolism, 2013
- Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7‐yr follow‐up from the ESCALATOR study in patients with β‐thalassaemiaEuropean Journal of Haematology, 2011
- On T2* Magnetic Resonance and Cardiac IronCirculation, 2011
- Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging studyHaematologica, 2011
- The inherited diseases of hemoglobin are an emerging global health burdenBlood, 2010
- Pancreatic iron loading predicts cardiac iron loading in thalassemia majorBlood, 2009
- Longitudinal analysis of heart and liver iron in thalassemia majorBlood, 2008
- Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2008